The reality (imo) is that the share price had gotten over-extended, near $40, on the expectation of a smooth filing of AA and all blessings by the FDA. These situations are never that seamless; there are always thorns somewhere.
The current situation appears to be one of stasis; we've reached equilibrium between the bull/bears. In the absence of significant news, we'll probably tread water around these levels (baring major mkt. correction) until the water clears, and AA filing is announced or denied.